Search
Results
showing 1-10 of 5287
Today — in the US and around the world
We will all need time to process the US election results and strategize how we navigate through them in the years ahead — as individuals, as a network of partners, and as advocates for choice, science, and rights. We look forward to working with our partners in protecting hard-fought gains and assessing the potential impact on PEPFAR, Global Fund support, and on US government aid agencies.
STIWatch Newsletter, November 2024
The past few months have brought exciting developments in the field of sexually transmitted infections. WHO released the global priorities for STIs, which included the need to develop low-cost, rapid STI point-of-care tests, vaccines, and communication strategies to increase STI awareness. But we continue to see a soaring rise in STI incidence and an underfunded infrastructure for researching new treatment, prevention and testing tools.
Years Ahead in HIV Prevention Research: Time to Market
This timeline shows the potential time points when the next-generation of HIV prevention options might find their way into new programs.
LEN Generics — Can we go faster?
The timeline for generic LEN for PrEP to come to market is expected to be significantly shorter than for CAB for PrEP. Bioequivalence (BE) testing for LEN, which demonstrates a generic product works in the body in the same way as the originator product, is likely to be six months, vs. the 18 months for CAB for PrEP, because of differences in the drug formulation.
showing 1-10 of 5287